Zobrazeno 1 - 10
of 202
pro vyhledávání: '"AE, adverse event"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stephen J. Thomas, John L. Perez, Stephen P. Lockhart, Subramanian Hariharan, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Ugur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, Claire Lu, Teresa C. Gentile, William C. Gruber
Publikováno v:
Vaccine
Introduction Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with
Autor:
Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, Masanori Ikeda, Xiaofei Hu, Kimitoshi Ikeda, John Liu, Takuya Sasaki, Alvina D. Chu, Henrique D. Teixeira, Hidehisa Saeki
Publikováno v:
JAAD International
JAAD International, Vol 6, Iss, Pp 27-36 (2022)
JAAD International, Vol 6, Iss, Pp 27-36 (2022)
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic
Autor:
Jun-Heng Bai, Xiao-Lu Ren, Wen-Wen Dong, Jie-Quan Yang, Meng-Sheng Cui, Jian-Jun Shi, Xiao-Fei Chang
Publikováno v:
Breast, Vol 59, Iss, Pp 44-50 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background Many breast cancer clinical trials with PARPi have been completed or are currently carried out, either by monotherapy or combined with chemotherapy. We aim to assess the efficacy and safety of PARPi in breast cancer patients as compared to
Autor:
Jin Gyu Jung, Sunghyun Kim, Bum Soo Kim, Anca Streinu-Cercel, Oana Săndulescu, Da Bee Jeon, Adrian Streinu-Cercel, Seul Gi Lee, Sang Joon Lee, Yeon Sook Kim, Yeo Jin Lee, Jin Yong Kim, Yeon Mi Lee, Min Kyung Kim, Jae-Hyeong Park, Jang Hee Hong, Jeong Eun Park, Young Rock Jang, Na Hyun Jung
Publikováno v:
Clinical Therapeutics
PURPOSE: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single as
Autor:
Paula K. Schweitzer, Atul Malhotra, Mark H. Gotfried, Russell Rosenberg, Geert Mayer, Kingman P. Strohl, Gary Zammit, Patricia Chandler, Michelle G. Baladi
Publikováno v:
Chest
Background Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with OSA (37.5-150 mg/d). Research Question Does solriamfetol
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3857-3868 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3857-3868 (2021)
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic
Publikováno v:
VideoGIE
Video Video 1 After insertion of the cholangioscope into the common bile duct, electrohydraulic lithotripsy was performed. All common bile duct stones were shattered and successfully removed using a basket and balloon catheter.
Autor:
João Santos-Antunes, Rui Morais, Pedro Pereira, Ana L. Santos, Eduardo Rodrigues-Pinto, Guilherme Macedo, Filipe Vilas-Boas
Publikováno v:
VideoGIE
Background and Aims Recent data support a role for endoscopic radiofrequency ablation (RFA) in unresectable cholangiocarcinoma by improving stent patency and overall survival. Methods We describe 3 patients with inoperable cholangiocarcinoma with jau